Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease.
T h e ne w e ngl a nd jou r na l o f m e dicine S pinal muscular atrophy (SMA) is a severe childhood monogenic disease resulting from loss or dysfunction of the gene encoding survival motor neuron 1 (SMN1). The incidence of this disease is approximately 1 in 10,000 live births, with a carrier frequency of 1 in 54. 1 SMA is characterized by the degeneration and loss of lower motor neurons, which leads to muscle atrophy. The disease is divided into four subtypes (1 through 4) on the basis of the age at onset and milestone achievement. SMA type 1 (SMA1) is the most severe form and most common genetic cause of death among infants with SMA. 2 There are two forms of SMN; SMN1 is the primary gene responsible for functional production of SMN protein. SMN2 preferentially excludes exon 7 during splicing 3 and, as a result, produces only a small fraction of functional SMN protein as compared with SMN1. Therefore, the SMN2 copy number modifies the disease phenotype, and the presence of two copies of SMN2 is associated with severe SMA1. 3 Infants with SMN1 biallelic deletions and two copies of SMN2 have a 97% risk of SMA1.
Recent studies of the natural history of SMA1 (historical cohort) showed that the median age at symptom onset among infants with the disease was 1.2 months (range, 0 to 4 months), and the disease was characterized by hypotonia, severe weakness from early infancy, and failure to sit without support. 4, 5 In infants with SMA1 who have two copies of SMN2, the median age at death or the need for noninvasive ventilation for at least 16 hours per day for at least 14 consecutive days (considered equivalent to permanent ventilation) was 10.5 months. 4 In one cohort of affected children, only 25% survived without permanent ventilatory support at 13.6 months, and 8% survived without this support by 20 months. 4 Another prospective, multicenter historical study sponsored by the National Institutes of Health (NeuroNEXT) 5 involving patients with two copies of SMN2 showed a median survival of 8 months (95% confidence interval, 6 to 17). All patients with SMA1 have a precipitous decline in respiratory and swallowing functions after birth and ultimately require mechanical nutritional support (through a nasogastric or gastrostomy tube) to maintain adequate nutrition and reduce the respiratory risks associated with aspiration. For patients with SMA1 in whom the onset of symptoms occurs by 3 months of age, most patients require feeding support by 12 months of age. 4 Patients with SMA1 also do not achieve major milestones in motor function and have a decline in function, as measured on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale, which ranges from 0 to 64, with higher scores indicating better motor function, a tool that is sensitive to minor changes in motor function, such as antigravity movements of limbs. [6] [7] [8] In a historical analysis of 34 patients with SMA1, all but 1 of the patients did not reach a score of at least 40 after 6 months of age. 4 In the NeuroNEXT cohort, CHOP INTEND scores decreased by a mean of 10.7 points from 6 months to 12 months of age. 5 Therapeutic strategies to increase levels of SMN protein in motor neurons have focused on enhancing the effectiveness of SMN2. One approach has been central nervous system delivery of nusinersen (Ionis Pharmaceuticals/Biogen), an antisense oligonucleotide that was developed to inhibit exon 7 splicing in SMN2. This drug has been shown to improve weakness in the murine model of severe SMA and to increase the median life span of affected mice from 16 days to 25 days. 9, 10 In December 2016, nusinersen was approved by the Food and Drug Administration for the treatment of SMA. This drug is administered by means of repeated intrathecal injections after four loading doses within the first 2 months of life.
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A potential alternative treatment for SMA1 is gene therapy, given as a one-time intravenous administration that delivers a copy of SMN in a self-complementary adeno-associated viral serotype 9 (scAAV9). (The coding region of this recombinant virus forms an intramolecular doublestranded DNA [or self-complementary] template.) This approach has induced SMN expression in motor neurons and peripheral tissues, which has countered the effects of SMA in a murine model and extended the average survival in this model from 15 days to 26 days with a low dose (6.7×10 13 vg per kilogram of body weight) and to more than 250 days with higher doses of the vector (2.0×10 14 and 3.3×10 14 vg per kilogram). [12] [13] [14] [15] In addition to crossing the blood-brain barrier and targeting central nervous system neurons at all regions of the spinal cord, 13 the systemic administration of AAV9-mediated gene therapy may be advantageous, given that SMN protein is ubiquitously expressed and SMA1 affects multiple systems (e.g., autonomic and enteric nervous systems, cardiovascular system, and pancreas 16, 17 ), A Quick Take is available at NEJM.org
Gene-Replacement Ther apy for Spinal Muscular Atrophy along with many cell types (e.g., heart, 18 pancreas, 16, 17 and skeletal muscle 19 ). The self-complementary feature of the vector combined with a hybrid cytomegalovirus enhancer-chicken betaactin promoter enables rapid and sustained expression of SMN. In April 2014, we initiated a study of gene-replacement therapy involving infants with SMA1 who received a one-time dose of scAAV9 with delivery of the human survival motor neuron gene (hSMN), under control of the chicken beta-actin promoter (scAAV9.CB.hSMN) (AVXS-101).
Me thods

Study Oversight
The study was approved by the institutional review board at Nationwide Children's Hospital in Columbus, Ohio. Written informed consent was obtained from the parents or legal guardians of the children. The sponsor, AveXis, provided data management and statistical analysis; the gene and vector were provided by the vector-manufacturing facility at Nationwide Children's Hospital. All the authors vouch for the fidelity of the study conduct to the protocol (available with the full text of this article at NEJM.org) and for the accuracy and completeness of the data, analysis, and reporting of adverse events. An independent data and safety monitoring committee monitored the integrity and safety of the study.
Patients and Study Procedures
All the patients had a genetically confirmed diagnosis of SMA1, homozygous SMN1 exon 7 deletions, and two copies of SMN2. Patients with the c.859G→C disease modifier in exon 7 of SMN2 were excluded. Details regarding the inclusion and exclusion criteria are provided in the protocol.
Patients were enrolled in two cohorts, according to the dose of gene therapy that was administered. Patients in cohort 1 received a low dose (6. The vector was delivered in normal saline (approximately 10 to 20 ml per kilogram) that was infused intravenously during a period of approximately 60 minutes. At the time of enrollment, some patients required enteral feeding by means of a gastrostomy or nasogastric tube, the choice of which was based on the preference of the parents or the primary physician. Once enrolled in the study, all the patients who required nutritional support underwent placement of a gastrostomy tube, and the tubes were not removed during the study.
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Outcomes
The primary outcome was the determination of safety on the basis of any treatment-related adverse events of grade 3 or higher. The secondary outcome was the time until death or the need for permanent ventilatory assistance. The latter was defined as at least 16 hours of respiratory assistance per day continuously for at least 14 days in the absence of an acute, reversible illness or a perioperative state. Exploratory outcomes included motor-milestone achievements (particularly, sitting unassisted) and CHOP INTEND scores. 7, 8 The maintenance of scores of more than 40 points has been considered to be clinically meaningful in SMA in the application of the CHOP INTEND scale. 4, 5 Sitting unassisted was evaluated and classified according to the following criteria: sitting unassisted for at least 5 seconds, according to item 22 of the Bayley Scales of Infant and Toddler Development gross motor subtest ("sitting unassisted") 21 ; sitting unassisted for at least 10 seconds, according to the World Health Organization (WHO) criteria ("sitting unassisted per WHO criteria") 22 ; and sitting unassisted for at least 30 seconds, according to item 26 of the Bayley Scales mentioned above ("independent functional sitting"). Major motor milestones were confirmed by means of an examination of video recordings of the patients by an independent reviewer. Compound muscle action potentials were recorded from surface electrodes at baseline and every 6 months after infusion. Data regarding compound muscle action potentials have not been fully analyzed and are not reported here.
Statistical Analysis
Safety analyses were performed in all the patients, who were also included in the primary analysis of survival (as defined above and in the protocol) and in analyses of changes on the CHOP INTEND scale from baseline to 1 month and 3 months. Such changes from baseline to the final visit were analyzed with the use of a mixed-effects model for repeated measurements. The mixed model included the fixed effects of cohort and visit and a covariate of baseline score. Milestone achievements and nutritional and ventilatory support were analyzed in cohort 2. Statistical analyses were performed with the use of SAS software, version 9.4. All comparisons with historical cohorts were solely descriptive.
R esult s
Patients
Of the 16 patients who were screened, 1 was excluded because of persistently elevated anti-AAV9 antibody titers (>1:50). Of the 15 patients who were included in the study, 3 were enrolled in the low-dose cohort 1 and 12 were enrolled in the high-dose cohort 2. The mean age of patients at the time of treatment was 6.3 months (range, 5.9 to 7.2) in cohort 1 and 3.4 months (range, 0.9 to 7.9) in cohort 2 (Table 1 ).
Survival and Permanent Ventilation
As of August 7, 2017 , all the patients had reached an age of at least 20 months and did not require permanent mechanical ventilation; the median age at their last pulmonary assessment was 30.8 months in cohort 1 and 25.7 months in cohort 2 ( Fig. 1) . In contrast, only 8% of the patients in a historical cohort did not require permanent mechanical ventilation. 4 At 29 months of age, one patient in cohort 1 required permanent ventilation because of hypersalivation. After salivarygland ligation, the requirement for the use of noninvasive ventilation was reduced by 25% to 15 hours per day.
Motor Function Assessments
All the patients in cohorts 1 and 2 had increased scores from baseline on the CHOP INTEND scale and maintained these changes during the study (Fig. 2) . Patients in cohort 2 had mean increases of 9.8 points at 1 month and 15.4 points at 3 months (P<0.001 for both comparisons); 11 patients attained and sustained scores of more than 40 points. At the study cutoff on August 7, 2017, patients in cohort 1 had a mean increase of 7.7 points from a mean baseline of 16.3 points, and those in cohort 2 had a mean increase of 24.6 points from a mean baseline of 28.2 points.
Motor Milestones in Cohort 2
A total of 11 of 12 patients in cohort 2 were able to sit unassisted for at least 5 seconds, 10 for at least 10 seconds, and 9 for at least 30 seconds (Table 2 ). A total of 11 achieved head control, 9 could roll over, and 2 were able to crawl, pull to stand, stand independently, and walk independently. Eleven patients attained the ability to speak. No patients in the historical cohorts had achieved any of these motor milestones and rarely had achieved the ability to speak.
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Pulmonary and Nutritional Status in Cohort 2
Among the 12 patients in cohort 2, 10 required noninvasive ventilation at baseline as compared with 7 who were independent of ventilatory as- sistance at the end of the study (Table 2 ). At baseline, 7 patients did not require enteral feeding, including 1 who later required placement of a gastrostomy tube after gene-replacement therapy, possibly in association with scoliosis surgery. Of the 5 patients who had received enteral feeding before gene-replacement therapy, 4 were able to feed orally by the end of the study; at last follow-up, 11 of the 12 patients had achieved or retained the ability to swallow independently and were able to feed orally.
Safety
As of August 7, 2017, a total of 57 serious adverse events were observed in 15 patients in the two cohorts. Of these events, investigators determined that 2 events were treatment-related grade 4 events on the basis of laboratory values, according to Common Terminology Criteria for Adverse Events (Table 3) . Patient 1 in cohort 1 had elevations in serum aminotransferase levels (35 times the upper limit of the normal range for alanine aminotransferase [ALT] and 17 times the upper limit for aspartate aminotransferase [AST]) without other liver-function abnormalities (i.e., total and indirect bilirubin and alkaline phosphatase) and without clinical manifestations. As described above, these elevations were attenuated by prednisolone treatment, which was subsequently administered in the remaining patients. One patient in cohort 2 required additional prednisolone to attenuate elevated serum ALT and AST levels (both 4 times the upper limit of the normal range). Of the 211 nonserious adverse events, 3 were deemed to be treatment-related and consisted of asymptomatic elevations in serum aminotransferase levels in 2 patients (ALT and AST, both less than 10 times the upper limit of the normal range), which were resolved without additional prednisolone treatment (Table 3 ). There were no other abnormalities on liver-function testing. Of the 15 patients, 14 had respiratory illnesses, which in children with SMA1 frequently result in death or the need for tracheostomy.
Discussion
A single intravenous infusion of adenoviral vector containing DNA coding for SMN in patients with SMA1 resulted in longer survival than in historical cohorts with this disease. 4 All 15 patients surpassed the previously reported median age of survival without permanent ventilation of 8 months 5 for patients with SMA1 with two SMN2 copies. All the patients also surpassed the benchmark of 20months, at which time only 8% of the patients with this disease typically survive without permanent ventilation. 4 Of the 12 patients in cohort 2, all but 1 achieved motor-function milestones that have not been reported in historical cohorts. 4, 6 The attained motor function was clinically meaningful, as reflected by feeding (hand to mouth), sitting, and talking. The majority of the patients who did not require supportive care at enrollment were free of nutritional support (6 of 7 patients) and ventilatory support (7 of 10 patients) at the end of the study. 4, 24 In the two cohorts, the patients had increases in the score on the CHOP INTEND scale from baseline. Within the first month in cohort 2, the mean increase was 9.8 points, in contrast to a decline of a mean of more than 10 points between 6 and 12 months of age in the historical cohort in the NeuroNEXT study. 5 Preclinical studies of SMN gene-replacement therapy in the SMNΔ7 mouse model showed improvements in survival and motor function with early treatment, presumably at a time when motor neurons are still intact. 14 The clinical findings in our study of early treatment reflected the direction of those in the preclinical studies. Two patients were able to crawl, stand, and walk without support after early treatment. Both of these patients had a family history of SMA, which probably contributed to the early diagnosis. Although all the patients in the two cohorts Gene-Replacement Ther apy for Spinal Muscular Atrophy T h e ne w e ngl a nd jou r na l o f m e dicine in our study have continued to have improvements in motor function, the preclinical and clinical data suggest a benefit for early treatment and newborn screening for SMA. 6 Serious adverse events caused by AAV genereplacement therapy were limited to elevated serum aminotransferase levels without other liver enzyme abnormalities approximately 3 weeks after treatment in two patients; two other patients had elevations that did not reach the cutoff for the definition of serious adverse events (i.e., >10 times the normal range). Elevations in liver enzymes were attenuated by prednisolone treatment. One patient did not pass screening owing to the presence of anti-AAV9 antibody, which is consistent with population studies that suggest a low rate of anti-AAV9 seropositivity among children and young adults and increasing rates of anti-AAV9 seropositivity among persons older than 40 years of age. 25 However, the presence of antibodies to the virus may be a limitation of AAV gene-replacement therapy.
This study used a single-group design with a historical cohort as a control, which is one of a limited number of options when the natural history of a disease is well characterized and lethal. In order to enroll a homogeneous sample that was similar to those in published historical studies, we restricted enrollment to include only symptomatic patients with SMA1 who had biallelic SMN1 mutations and two SMN2 copies and did not enroll patients with the c.859G→C genetic modifier in exon 7 of SMN2. 26 The natural course of disease for children with the latter genetic profile is universally poor.
In conclusion, a one-time intravenous infusion of a high dose of adenoviral vector containing DNA coding for SMN in patients with SMA1 resulted in extended survival, improved motor function, and increased scores on the CHOP INTEND scale to levels that had not previously been observed in this disease. Such improvements resulted in a lower percentage of patients who needed supportive care than those in historical studies. At the time of this report, no waning of effect or clinical regression in motor function had been reported in follow-up of up to 2 years. Several patients had transient and asymptomatic elevations in aminotransferase levels. Further studies are necessary to assess the longterm safety and durability of gene-replacement therapy in patients with SMA1.
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